Table 4.

Comparison of HIDs with ISDs in hematologic malignancies

Study	Disease	No. (HID vs. ISD)	Protocol in HIDs	Survival and relapse
Wang, 2015	AML in CR1	231 vs. 219	G-CSF and ATG	3-year DFS 74% vs. 78% (P = 0.34); relapse 15% vs. 15% (P = 0.98)
Wang, 2016	ALL in CR1	103 vs. 83	G-CSF and ATG	3-year DFS 61% vs. 60%, (P = 0.91), relapse 18% vs. 24% (P = 0.30)
Wang, 2016	MDS	226 vs. 228	G-CSF and ATG	4-year RFS 58% (HLA 3/6) vs. 63% (HLA 4–5/6) vs. 71% (ISD) (P = 0.14)
Ghosh, 2016	Lymphoma	180 vs. 807	PT-Cy based	3-year PFS 48% vs. 48% (P = 0.96), disease progression (37% vs. 40%, P = 0.51)
Chang, 2017	AML MRD+	56 vs. 20#	G-CSF and ATG	4-year LFS 80% vs. 48% (P = 0.007), relapse 13% vs. 36% (P = 0.017)
Chang, 2020	ALL MRD+	169 vs. 39	G-CSF and ATG	3-year LFS 65% vs. 43% (P = 0.023), relapse 23% vs. 47% (P = 0.006)
Yu, 2019	High-risk AML	83 vs. 106	G-CSF and ATG	3-year RFS 63% vs. 43% (P = 0.035), relapse 14% vs. 24% (P = 0.101)

^#Extracted from the prospective cohort. The bold values refer to “P <0.05” with significance.